In The Newsalzheon2024-08-09T11:20:07-04:00

In the News

Alzheon nabs $100M in series E to advance oral Alzheimer’s drug

BioWorld

Alzheimer’s Drug Developer Alzheon Closes $100M Series E Financing

GEN

With fresh $100M, Alzheon lays out strategy for Alzheimer’s approval next year

Firstword Pharma

Breakthroughs in Alzheimer Research Pave Way for New Era of Treatment: Martin Tolar, MD, PhD

NeurologyLive

Beginning a New Era of Precision Alzheimer’s Therapeutics

Inside Precision Medicine

Newsweek Investment Report: Interview with Dr. Martin Tolar, President & CEO of Alzheon, Inc. January 2024

Newsweek Investment Reports

ALZ-801 for 2 years seen to sustain cognition in early Alzheimer’s

Alzheimer's News Today

Alzheimer Agent ALZ-801 Improves Cognition, Reduces Relevant Biomarker Levels in 2-Year Analysis

neurologylive.com